Enzalutamide

Type: Keyphrase
Name: Enzalutamide
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

News NICE guidance on enzalutamide for metastatic hormonerelapsed prostate cancer

, the National Institute for Health and Care Excellence (NICE) recommended enzalutamide, within its marketing authorisation, for the treatment of metastatic hormone-relapsed prostate cancer that has progressed during or after docetaxe...Related Biotechnology, ... [Published BioPortfolio - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Key Genitourinary Oncology Takeaways from ASCO 2014

WALTER STADLER, MD, FACPImage ToolsThe GU sessions at ASCO 2014 included one major practice-changing and several additional interesting and timely presentations. The obvious practice-changing study was the ECOG 3805 CHAARTED study of standard androgen ... [Published Oncology Times - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 5 reports

NICE Approves Xtandi and Yervoy

Cost regulators for the National Health Service in England and Wales have this morning issued guidance recommending the use of Bristol-Myers Squibb's Yervoy (ipilimumab) for skin cancer and Astellas' Xtandi (enzalutamide) for prostate cancer.First-line ... [Published American Journal of Managed Care - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

NHS limits use of life-extending prostate cancer drug

Enzalutamide will not be given to men who have already received another new treatmentThousands of men with advanced prostate cancer are to miss out on a life-extending drug because of new NHS restrictions, it has been reported.Enzalutamide prolongs life ... [Published Health Insurance Daily - Jul 23 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Further analysis of PREVAIL: Enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Download PDF This is a temporary file and hence do not link it from a website, instead link the URL of this page if you wish to link the PDF file.To read this article you will require Adobe© Acrobat Reader, if you do not have this installed you can download ... [Published Asian Journal of Andrology - Jul 15 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Terminally-ill cancer patient needs £3,000-a-month for life-extending treatment

CANCER DRUG: Jemma Warburton is organising a fundraising night to raise money for terminally-ill Kevin Boland, who has been refused £3,000-a-month drug which could potentially extend his life Picture: SARAH CALDECOTTA TERMINALLY ill cancer sufferer needs ... [Published Northern Echo - Jul 15 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Astellas Details Pipeline Progress at R&D Meeting

/PRNewswire/ --Astellas announced progress on the Company's efforts to reshape its research framework at its R&D meeting held in Tokyo on the 10 th July. The meeting provided an opportunity for Astellas to present a comprehensive overview of the Company's ... [Published OSIX News - Jul 11 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Medivation Announces Change in Executive Management Team

SAN FRANCISCO, CA -- (Marketwired) -- 07/10/14 -- Medivation, Inc. (NASDAQ: MDVN) today announced Dawn Svoronos (formerly Graham) has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, chief executive officer and president ... [Published Pettinga Financial Advisors - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

AR-V7 Predicts Resistance to Enzalutamide and Abiraterone in Men With Castration-Resistant Prostate Cancer

Emmanuel S. Antonarakis, MDRole of AR-V7 in Prostate Cancer TherapyIf these results are supported by larger studies, detection of AR-V7 in circulating tumor cells may be used as a biomarker to predict resistance to enzalutamide, abiraterone, and AR-targeted ... [Published The ASCO Post - Jul 09 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

Progress in the treatment of advanced prostate cancer - Abstract

The androgen receptor (AR) is the most significant target for patients with metastatic castration-resistant prostate cancer (mCRPC).There is now irrefutable evidence that the AR axis is functional in most patients throughout the history of prostate cancer, ... [Published UroToday - Jul 04 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Prostate cancer Niclosamide jumps the hurdle of enzalutamide resistance

Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: Prostate cancer: Niclosamide jumps the hurdle of enzalutamide resistanceNEXT ARTICLE More From BioPortfolio on "Prostate cancer: Niclosamide jumps the hurdle of enzalutamide ... [Published BioPortfolio - Jul 01 2014]
First reported Jun 29 2014 - Updated Jun 30 2014 - 2 reports

[News] Enzalutamide in castration-resistant prostate cancer

Enzalutamide, an oral androgen-receptor inhibitor, prolongs the time until radiographic progression and improves overall survival in men with metastatic castration-resistant prostate cancer who have not previously undergone chemotherapy, according to ... [Published Lancet Oncology - Jun 30 2014]

Quotes

...Therefore, if possible, the concomitant use of these TKIs with a proton-pump inhibitor, H₂ antagonist, or antacid "should be avoided, or the time of drug intake should be separated by several hours at least" the authors advise
...Professor Carole Longson, centre for health technology evaluation director at NICE, said: "Enzalutamide works in a different way to the other options currently available for treating prostate cancer. As there are few treatments available for patients at this stage of prostate cancer, this is really good news for patients." The company is currently seeking a new EU approval for Xtandi for the treatment of adult men with metastatic castration-resistant prostate cancer who...
"A panel of 21 physicians from the European consensus panel of prostate cancer expert agreed and published in European Journal of Cancer that PROVENGE is an appropriate option for the treatment of asymptomatic, minimally symptomatic metastatic castrate resistant prostate cancer. 70% of these physicians support the use of PROVENGE prior to Abiraterone or Enzalutamide."
Professor Carole Longson, centre for health technology evaluation director at NICE, says in a statement: "For many years the treatments available for advanced skin cancer have been very limited and in some cases restricted to palliative care. However, new drugs such as ipilimumab can make a real difference."

More Content

All (135) | News (103) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Drugs to Avoid in Patients on Tyrosine Kinase I... [Published Diabetes Care - Jul 25 2014]
Changing paradigms in management of metastatic ... [Published 7thSpace - Jul 25 2014]
Astellas' Xtandi receives new NICE prostate can... [Published Zenopa - Jul 25 2014]
3 Convincing Reasons To Buy Dendreon [Published Seeking Alpha - Jul 24 2014]
News NICE guidance on enzalutamide for metastat... [Published BioPortfolio - Jul 24 2014]
Evolution of androgen receptor targeted therapy... [Published UroToday - Jul 24 2014]
Key Genitourinary Oncology Takeaways from ASCO ... [Published Oncology Times - Jul 23 2014]
NICE Approves Xtandi and Yervoy [Published American Journal of Managed Care - Jul 23 2014]
NHS limits use of life-extending prostate cance... [Published Health Insurance Daily - Jul 23 2014]
UK’s NICE recommends Xtandi and Yervoy under pa... [Published Pharma Letter - Jul 23 2014]
NICE backs 2 new cancer treatments [Published BootsWebMD - Jul 23 2014]
UKs NICE recommends Xtandi and Yervoy under pat... [Published BioPortfolio - Jul 23 2014]
NICE ‘yes’ for cancer drugs [Published Pharmafocus - Jul 23 2014]
Cancer drugs Yervoy, Xtandi get NICE thumbs up [Published Pharma Times - Jul 23 2014]
NICE backs cancer drugs from Astellas and BMS [Published PMLive - Jul 23 2014]
An oncologist’s argument for funding your own c... [Published Quartz - Jul 18 2014]
Medivation makes change to executive management... [Published Manufacturing Chemist - Jul 17 2014]
Novel Bone-Targeting Agents in Prostate Cancer [Published General Medicine eJournal - Jul 16 2014]
Further analysis of PREVAIL: Enzalutamide use i... [Published Asian Journal of Andrology - Jul 15 2014]
Terminally-ill cancer patient needs £3,000-a-mo... [Published Northern Echo - Jul 15 2014]
Astellas details pipeline progress at R&D meeting [Published Pharma Letter - Jul 12 2014]
Astellas Details Pipeline Progress at R&D Meeting [Published TickerTech.com - Jul 11 2014]
Astellas Details Pipeline Progress at R&D Meeting [Published OSIX News - Jul 11 2014]
Medivation Announces Change in Executive Manage... [Published Pettinga Financial Advisors - Jul 10 2014]
Medivation Announces Change in Executive Manage... [Published Franklin Credit Management Corporation - Jul 10 2014]
AR-V7 Predicts Resistance to Enzalutamide and A... [Published The ASCO Post - Jul 09 2014]
Urologists Face New Paradigm for Metastatic Pro... [Published American Journal of Public Health - Jul 09 2014]
Progress in the treatment of advanced prostate ... [Published UroToday - Jul 04 2014]
Patient-reported outcome labeling claims and me... [Published 7thSpace - Jul 04 2014]
Aegis Capital Believes Seragon Deal Underscores... [Published Benzinga.com - Jul 02 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Articles Most Widely Covered in the Press - Jun 10 2014]
Prostate cancer is the most commonly diagnosed cancer and the sixth leading cause of cancer-related death among men worldwide.1 Strategies to block androgen-receptor signaling have formed the backbone of prostate-cancer therapy since the first description ...
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Most Viewed Articles - Week - Jun 04 2014]
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Most Emailed Articles - Jun 04 2014]
New Drug May Boost Survival for Advanced Prosta... [Published MedlinePlus Health News - Jun 02 2014]
Enzalutamide also delays need for chemotherapy, researchers report Source: HealthDayRelated MedlinePlus Pages: Medicines , Prostate Cancer ...
New England Journal of Medicine Publishes Resul... [Published PR Newswire: Entertainment & Media - Jun 01 2014]
NORTHBROOK, Ill. and SAN FRANCISCO, JUNE 1, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced the online publication in the New England ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Astellas Announces Marketing Approval in Japan ... [Published Financial Services - Mar 24 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.